Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
A panel of experts discusses the evolution of BPH treatment, as well as how their practices have been affected by COVID-19.
An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with ...
In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics. In this video, recorded at the 2025 LUGPA Annual Meeting, Arpeet Shah, MD, a urologist ...
TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...
The gemcitabine intravesical system offers localized chemotherapy delivery, providing a promising option for patients who have failed previous treatments. Successful implementation of new therapies ...
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
Louise K. Kostos, MBBS, FRACP, PhD candidate, outlines initial findings from the phase 1/2 AlphaBet trial. Data from the phase 1/2 AlphaBet trial (NCT05383079) were presented at the 2025 European ...
The KEYNOTE-905 trial showed significant survival benefits with enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer, suggesting a new standard for cisplatin-ineligible patients. The ...
The findings revealed that patients prioritized improvements in overall survival and reductions in cancer recurrence at 5 years over all other treatment factors In this interview, Angela B. Smith, MD, ...
Adjuvant durvalumab plus tremelimumab improved DFS in resected RCC, especially in high-risk patients, with a 43% reduction in recurrence risk. The trial enrolled patients into three arms, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback